Sanofi's rilzabrutinib gains breakthrough therapy status in US, orphan drug designation in Japan
Source: SeekingAlpha
2026-02-09 01:33:54 ET
Read the full article on Seeking Alpha
For further details see:
Sanofi’s rilzabrutinib gains breakthrough therapy status in US, orphan drug designation in Japan
Banco Santander S.A. Sponsored ADR
NASDAQ: SAN
SAN Trading
-1.85% G/L:
$10.86 Last:
7,497,165 Volume:
$11.05 Open:
SAN Latest News
February 03, 2026 01:38:00 pm
Webster Financial Corporation Enters Into Merger Agreement With Banco Santander, S.A. for $12.3 Billion
SAN Stock Data
$212,542,521,684
14,572,031,202
2.7%
312
N/A
Banking
Finance
ES
Boadilla del Monte
